Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1996-03-22
1999-03-16
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241331, 5303873, 53038822, A61K 39395
Patent
active
058826440
ABSTRACT:
The invention relates to monoclonal antibodies, humanized monoclonal antibodies and functional derivatives thereof specific for the platelet-derived growth factor receptor .beta.. Methods of use of the antibody, particularly in ameliorating restenosis, are also provided.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio et al.
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5468468 (1995-11-01), LaRochelle et al.
patent: 5620687 (1997-04-01), Hart et al.
Lindmark et al (Dec. 1993) Lab. Invest. vol. 69(6):682-9.
Chaudhry et al. (Feb. 15 1992) Cancer Res. vol. 52(4):1006-12.
Claesson-Welsh, "Platelet-derived growth factor receptor signals" J. Biol. Chem. (1994) 269:32023-32026.
Kawahara et al., "Monoclonal antibody C3.1 is a platelet derived growth factor (PDGF) antagonist" Biochim. Biophys. Res. Commun. (1987) 147:839-845.
Ronnstrand et al., "Characterization of two monoclonal antibodies reactive with the external domain of the platelet-derived growth factor receptor" J. Biol. Chem. (1988) 263:10429-10435.
Kanakaraj et al., "Ligand-induced interaction between .alpha.--and .beta.-type platelet-derived growth factor (PDGF) receptors: Role of receptor heterodimers in kinase activation" Biochem. (1991) 30:1761-1767.
Claesson-Welsh et al., "Identification and structural analysis of the A type receptor for platelet-derived growth factor" J. Biol. Chem. (1989) 264:1742-1747.
Seifert et al., "Two different subunits associate to create isoform-specific platelet-derived growth factor receptors" J. Biol. Chem. (1989) 264:8771-8778.
Kumjian et al., "Platelet-derived growth factor (PDGF) binding promotes physical association of PDGF receptor with phospholipase C" Proc. Natl. Acad. Sci. USA (1989) 86:8232-8236.
Bishayee et al., "Characterization of a novel anti-peptide antibody that recognizes a specific conformation of the platelet-derived growth factor receptor" Mol. Cell Biol. (1988) 8:3696-3702.
Hart et al., "Synthesis, phosphorylation, and degradation of multiple forms of the platelet-derived growth factor receptor studied using a monoclonal antibody" J. Biol. Chem. (1987) 262:10780-10785.
Escobedo et al., "Platelet-derived growth factor receptors expressed by cDNA transfection couple to a diverse group of cellular responses associated with cell proliferation" J. Biol. Chem. (1988) 263:1482-1487.
Daniel et al., "Biosynthetic and glycosylation of cell surface platelet-derived growth factor receptors" J. Biol. Chem. (1987) 262:9778-9784.
Keating et al., "Processing of the platelet-derived growth factor receptor" J. Biol. Chem. (1987) 262:7932-7937.
Kazlauskas et al., "Phosphorylation of the PDGF receptor .beta. subunit creates a tight binding site for phosphatidylinositol 3 kinase" EMBO J. (1990) 9:3279-3286.
Holmes et al., "Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry" J.Amer. Coll. Cardiol. (1988) 12:1149-1155.
Kohler et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion" Eur. J. Immunol. (1976) 6:511-519.
Gillam et al., "Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length" Gene (1979) 8:81-97.
Roberts et al., "Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering" Nature (1987) 328:731-734.
Thorpe et al., "Monoclonal antibody-toxin conjugates: aiming the magic bullet," Monoclonal Antibodies in Clinical Medicine, (1982) McMichael et al., eds., Academic Press, pp. 168-190.
Vitetta et al., "Redesigning nature's poisons to create anti-tumor reagents" Science (1987) 238:1098-1104.
Winter et al., "Man-made antibodies" Nature (1991) 349:293-299.
Olsnes et al., "Chimeric Toxins," Pharmac. Ther. (1982) 15:355-381.
Chatal et al., "Clinical prospective study with radioiodiated monoclonal antibodies directed against colorectal cancer" Monoclonal Antibodies for Cancer Detection and Therapy Baldwin et al. eds., (1985) Academic Press, pp. 159-180.
Jansen et al., "Efficiency and tolerance of the treatment with immuno-A-chain-toxins in human bone marrow transplantations" Monoclonal Antibodies for Cancer Detection and Therapy Baldwin et al., eds. (1985) Academic Press, pp. 223-248.
Myers, "The use of immuno-toxins to eliminate tumour cells from human leukemic marrow autografts" Monoclonal Antibodies from Cancer Detection and Therapy Baldwin et al., eds., (1985) Academic press, pp. 223-248.
Glaser et al., "Dissection of the combining site in a humanized anti-Tac antibody" J. Immunol. (1992) 149:2607-2614.
Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo" Biotechnology (1992) 9:266-271.
Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene" J. Exp. Med. (1992) 17:217-225.
Levitt, "Molecular dynamics of native protein. I. Computer simulation of trajectories" J. Mol. Biol. (1983) 168:595-620.
Dohlsten et al., "Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy" Proc. Natl. Acad. Sci. USA (1994) 91:8945-8949.
Bird et al., "Single-chain antigen-binding proteins" Science (1988) 242:423-426.
Fiedler et al., "High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds" Biotechnology (1995) 13:1090-1093.
Kanehisa, "Use of statistical criteria for screening potential homologies in nucleic acid sequences" Nucl. Acids Res. (1984) 12:203-213.
Cockett et al., "High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification" Bio/Technology (1990) 8:662-667.
Serruys et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II pilot study" Circ. (1996) 93:412-422.
Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen" J. Immunol. (1992) 148:1149-1154.
Escobedo et al., "Platelet-derived growth factor receptors expressed by cDNA transfection couple to a diverse group of cellular responses associated with cell proliferation" J. Biol. Chem. (1988) 263:1482-1487.
Chen et al., "High efficiency transformation of mammalian cells by plasmid DNA" Mol. Cell. Biol. (1987) 7:2745-2752.
Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" Proc. Natl. Acad. Sci. USA (1989) 86:10029-10033.
Ellison et al., "Linkage and sequence homology of two human immunoglobulin .gamma. heavy chain constant region genes" Proc. Natl. Acad. Sci. USA (1982) 79:1984-988.
Horgan et al., "Studies on antigen binding by intact and hinge-deleted chimeric antibodies" J. Immunol. (1993) 150:5400-5407.
Queen et al., "Fine mapping of an immunoglobulin gene activator" Mol. Cell. Biol. (1984) 4:1042-1049.
Afink et al., "Molecular cloning and functional characterization of the human platelet-derived growth factor .alpha. receptor gene promoter" Oncogene(1995)10:1667-1672.
Ahlman et al., "Growth regulation in carcinoid tumors" Endocrinology and Metabolism Clinics of North America (1993)22:889-915.
Ascoli et al., "Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions" J. Clin. Cytology and Cytopathology (1995) 39:613-622.
Bishayee, S., "A novel 200 kDa plasma membrane glycoprotein with high basal tyrosine kinase activity in tumor cells" Indian J. Biochem. Biophy. (1997) 34:18-24.
Bohling et al., "Expression of growth facto
Chang Chung Nan
Landolfi Nicholas F.
Martin Ulrich
Boehringer Mannheim GmbH
Chan Christina Y.
Nolan Patrick
Protein Design Labs, Inc.
LandOfFree
Monoclonal antibodies specific for the platelet derived growth f does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies specific for the platelet derived growth f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies specific for the platelet derived growth f will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-814736